In clinical trials of CAR T-cell therapies and real-world studies published to date, there is a paucity of data on outcomes by race and ethnicity. In a study presented by Locke et al at the 2022 ASCO Annual Meeting, a research team examined outcomes by race and ethnicity among patients with large B-cell lymphoma who received the CAR T-cell therapy axicabtagene ciloleucel in the real-world setting.
